

Informazione Regolamentata n. 0097-16-2026	Data/Ora Inizio Diffusione 29 Gennaio 2026 12:00:10	Euronext Milan
--	--	----------------

Societa' : CIR

Utenza - referente : CIRNSS02 - Claudio Patrian

Tipologia : 3.1

Data/Ora Ricezione : 29 Gennaio 2026 12:00:10

Data/Ora Inizio Diffusione : 29 Gennaio 2026 12:00:10

Oggetto : Completion of the acquisition of 40.23% of KOS S.p.A.

Testo del comunicato

Vedi allegato



press release

Completion of the acquisition of 40.23% of KOS S.p.A.

Milan, 29 January 2026 – CIR S.p.A. (“CIR”) announces that today it has completed the acquisition of the 40.23% stake in the share capital of KOS S.p.A. held by F2i Healthcare S.p.A., pursuant to the binding agreement signed on 19 November 2025. The acquisition was carried out by CIR Investimenti S.p.A, a company wholly owned by CIR S.p.A..

Completion of the transaction followed the receipt of the required regulatory approvals, including those under Italian Golden Power and Italian antitrust regulations, as well as German antitrust rules, and the satisfaction of all the conditions precedent.

The purchase price for the shares amounts to €220.0 million. In accordance with the terms of the agreement, prior to closing KOS distributed an extraordinary reserve totaling €24.86 million.

The earn-out mechanisms and the anti-embarrassment clause remain applicable, in accordance with the terms already disclosed on 19 November 2025.

The transaction was financed by CIR using part of its available liquidity.

Following completion of the transaction, CIR holds, directly or indirectly, 100% of the share capital of KOS S.p.A.

CIR Group contacts:

Press Office

Dini Romiti Consulting

Angelo Lupoli

alupoli@dr-cons.it

infostampa@cirgroup.com

Investor Relations

Alix De Benedetti

ir@cirgroup.com

Corporate Secretariat

Antonio Segni

Flavia Torriglia

segreteriasocietaria@cirgroup.com

Ph: +39 02 722701

cirgroup.it

Fine Comunicato n.0097-16-2026

Numero di Pagine: 3